Patient Characteristics
| Characteristic | Number of patients |
| American Joint Committee on Cancer clinical stage* | |
| IIA | 11 (21.5%) |
| IIB | 13 (25.5%) |
| IIIA | 12 (23.5%) |
| IIIB | 14 (27.5%) |
| IIIC | 1 (2%) |
| Tumor type | |
| Invasive ductal, no special type | 45 (88%) |
| Metaplastic | 3 (6%) |
| Lobular | 3 (6%) |
| Grade | |
| 1 | 4 (8%) |
| 2 | 28 (55%) |
| 3 | 17 (33%) |
| Unknown | 2 (4%) |
| ER status† | |
| Positive | 30 (59%) |
| Negative | 21 (41%) |
| HER2 status‡ | |
| Positive | 12 (23.5%) |
| Negative | 39 (76.5%) |
| Triple-negative status | |
| Triple-negative | 13 (25.5%) |
| Not triple-negative | 38 (74.5%) |
| Surgery | |
| Breast-conserving surgery | 25 (49%) |
| Mastectomy | 26 (51%) |
| Pathologic response | |
| Responders | 27 (53%) |
| Nonresponders | 24 (47%) |
↵* Version 7 (16) according to clinical examination and conventional imaging findings.
↵† Tumors were considered positive for ER (estrogen receptor) if >10% of cells showed staining by immunohistochemistry.
↵‡ Tumors were considered to be positive for HER2 if >30% of invasive tumor cells showed definite membrane staining resulting in so-called fishnet appearance.